Open AccessMacromolecular Viral Entry Inhibitors as Broad‐Spectrum First‐Line Antivirals with Activity against SARS‐CoV‐2
Author(s) -
Groß Rüdiger,
Dias Loiola Lívia Mesquita,
Issmail Leila,
Uhlig Nadja,
Eberlein Valentina,
Conzelmann Carina,
Olari LiaRaluca,
Rauch Lena,
Lawrenz Jan,
Weil Tatjana,
Müller Janis A.,
Cardoso Mateus Borba,
Gilg Andrea,
Larsson Olivia,
Höglund Urban,
Pålsson Sandra Axberg,
Tvilum Anna Selch,
Løvschall Kaja Borup,
Kristensen Maria M.,
Spetz AnnaLena,
Hontonnou Fortune,
Galloux Marie,
Grunwald Thomas,
Zelikin Alexander N.,
Münch Jan
Publication year - 2022
Publication title -
advanced science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.388
H-Index - 100
ISSN - 2198-3844
DOI - 10.1002/advs.202201378
Subject(s) - viral envelope , virology , viral entry , virus , in vitro , broad spectrum , cell culture , covid-19 , coronavirus , biology , merkel cell polyomavirus , chemistry , microbiology and biotechnology , viral replication , medicine , biochemistry , combinatorial chemistry , genetics , disease , merkel cell carcinoma , pathology , carcinoma , infectious disease (medical specialty)
Abstract Inhibitors of viral cell entry based on poly(styrene sulfonate) and its core–shell nanoformulations based on gold nanoparticles are investigated against a panel of viruses, including clinical isolates of SARS‐CoV‐2. Macromolecular inhibitors are shown to exhibit the highly sought‐after broad‐spectrum antiviral activity, which covers most analyzed enveloped viruses and all of the variants of concern for SARS‐CoV‐2 tested. The inhibitory activity is quantified in vitro in appropriate cell culture models and for respiratory viral pathogens (respiratory syncytial virus and SARS‐CoV‐2) in mice. Results of this study comprise a significant step along the translational path of macromolecular inhibitors of virus cell entry, specifically against enveloped respiratory viruses.